Cardiff Oncology's onvansertib may overcome Zytiga resistance in prostate cancer

• New efficacy data from ongoing Phase 2 trial of Cardiff Oncology's (NASDAQ:CRDF) onvansertib in combination with J&J's Zytiga (abiraterone) and prednisone for metastatic castration-resistant prostate cancer, achieves the primary endpoint of disease control in patients showing initial resistance to J&J's Zytiga (abiraterone).
• 8 of 26 (31%) evaluable patients achieved the primary endpoint of disease control (defined by a lack of prostate specific antigen progression) after 12 weeks of treatment, and 14 of 26 patients had stable disease (SD).
• 8 of 26 evaluable patients had durable SD of more than 7 months.
• Of 8 patients harboring AR alterations associated with Zytiga resistance, 3 achieved disease control at 12 weeks, 4 had SD at 12 weeks and 3 had durable SD (>7 months).
• Safety was demonstrated across all three different dose and dosing schedule cohorts, as well as the potential clinical benefit for patients with the basal molecular tumor subtype.
• In February this year, interim results from a Phase 2 trial evaluating onvansertib, combined with J&J's Zytiga (abiraterone acetate) and prednisone, demonstrated lower PSA levels in 86% (n=6/7) of patients.
• https://seekingalpha.com/news/3623677-cardiff-oncologys-onvansertib-may-overcome-zytiga-resistance-in-prostate-cancer